Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up After Strong Earnings

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) shares gapped up prior to trading on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $19.81, but opened at $22.48. Amphastar Pharmaceuticals shares last traded at $21.92, with a volume of 146,469 shares traded.

The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. The company had revenue of $183.90 million during the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.

Trending Headlines about Amphastar Pharmaceuticals

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Adjusted EPS beat estimates: Amphastar reported adjusted earnings of $0.91 per share, up from $0.85 a year earlier and above consensus estimates ranging from $0.62 to $0.66. GAAP earnings were $0.67 per share. Amphastar Pharmaceuticals Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Revenue also topped expectations: Second-quarter net revenue was $183.9 million, compared with analysts’ average estimate of approximately $179.9 million. The company generated $30.3 million in GAAP net income and $40.8 million in adjusted net income. Amphastar Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: Profitability remains solid: Amphastar reported an 11.0% net margin and 15.12% return on equity, while its quick and current ratios of 2.82 and 3.85 indicate substantial short-term liquidity. These figures support the stock’s favorable reaction to the earnings release. Amphastar Quarterly Earnings Results
• Neutral Sentiment: Investors will likely focus next on management’s outlook and commentary from the Q2 earnings call, particularly whether the earnings momentum can continue. Amphastar Q2 2026 Earnings Call Transcript

Analyst Upgrades and Downgrades

AMPH has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, July 8th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Barclays dropped their price objective on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Wednesday, June 3rd. Finally, Bank of America reiterated an “underperform” rating and set a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Six investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals has an average rating of “Reduce” and an average price target of $22.17.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP grew its holdings in shares of Amphastar Pharmaceuticals by 41.6% during the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock worth $33,134,000 after buying an additional 363,216 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in Amphastar Pharmaceuticals by 382.9% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 392,310 shares of the company’s stock valued at $10,455,000 after buying an additional 311,071 shares during the last quarter. UBS Group AG lifted its stake in Amphastar Pharmaceuticals by 367.2% in the 3rd quarter. UBS Group AG now owns 312,274 shares of the company’s stock valued at $8,322,000 after acquiring an additional 245,440 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $4,689,000. Finally, Dimensional Fund Advisors LP boosted its position in Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after acquiring an additional 228,262 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Up 9.7%

The stock has a market cap of $957.86 million, a price-to-earnings ratio of 13.09, a P/E/G ratio of 4.27 and a beta of 0.89. The business has a 50-day simple moving average of $19.63 and a two-hundred day simple moving average of $21.40. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.82 and a current ratio of 3.85.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.